Improving Quality of Life and Daily Life Activities With Bioarginine in Patients With COPD
- Registration Number
- NCT05412160
- Lead Sponsor
- University of Milan
- Brief Summary
Different studies have suggested that COPD is associated with elevated alveolar NO and increased expression of NOS2 in alveolar walls, small airway epithelium and vascular smooth muscle. Furthermore, arginase activity in COPD is shown to correlate inversely with total NO metabolite in sputum and with pre- and post- bronchodilator FEV1; at the same time ADMA levels in serum is shown to be correlated with airway resistance and ADMA in COPD airways was documented to be able to shift the L-arginine metabolism towards the arginase pathway. As demonstrated in a guinea pig model, the arginase inhibition can shift the L-ornitine: L-citrulline ratio towards L-citrulline, preventing neutrophilia, mucus hypersecretion and collagen synthesis. Thus, increasing substrate availability for NOS by arginase inhibition or supplementation of L-arginine or L-citrulline or a combination thereof, may represent a window of opportunity in patients with COPD.
The present study was constructed in order to investigate as a primary objective whether in symptomatic patients with COPD, daily bioarginine on top of chronic inhaled therapy can improve patients' respiratory symptoms and dyspnea during daily life activities. The secondary objective of the study is to determine whether there is any correlation between improvement in respiratory symptoms and distance walked at the 6MWT and lung function parameters. In order to do so, the investigators designed a multi center, interventional, prospective, randomized, controlled vs placebo, proof of concept study: COPD patients will be randomized to receive BioArginine twice daily on top of chronic inhaled therapy or to continue their chronic Inhaled therapy plus placebo for 6 weeks. In order to evaluate the impact on respiratory symptoms and dyspnea the CRQ (Chronic Respiratory disease Questionnaire) and the LCADL (London Chest Activities of daily Living) Scale, as well as the 6MWT, will be used.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 152
- > 40 years old
- Smoke history >10 pack years (PYs)
- Forced expiratory volume (FEV1 70-40% predicted)
- COPD Assessment Test score >= 10
- Stable Inhaled therapy in the three months prior to study enrollment
- Exacerbations in the three months prior to study enrolment
- Dementia and inability to perform study test bundles
- Interstitial lung disease
- History of asthma
- Patients unable to perform a 6MWT or necessitating a walker to ambulate
- Long term oxygen therapy (excluding patients on nocturnal O2 therapy)
- Patients enrolled In pulmonary rehabilitation programs during the study or that have completed a pulmonary rehabilitation program in the 6 months before study enrollment
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description ARM B - placebo receivers Placebo Patients will be randomized to receive placebo twice daily on top of usual chronic inhaled therapy ARM A - BioArginine receivers Arginine Patients will be randomized to receive BioArginine C™ twice daily on top of usual chronic inhaled therapy
- Primary Outcome Measures
Name Time Method To compare changes in CRQ from baseline and after 6 weeks in the interventional arm compared with the control group 6 weeks Patients will undergo the assesment of the Chronic Respitatory Qestionnaire at the time of study erollment and after 6 weeks of treatment with bioarginine or placebo.
The questionnaire contains 20 questions which can be divided into four domains:
* Dyspnoea (5 questions), The dyspnoea domain is "individualised" which means that it is made up of five activities chosen by a patient to cause the greatest shortness of breath. The patient then rates the dyspnoea on these self-selected activities during subsequent administrations of the CRQ.
* Fatigue (4 questions),
* Emotional functioning (7 questions),
* Mastery (4 questions).
* Answers can be scored on a seven point scale ranging from 1 which indicates maximum impairment to 7 which indicates no impairment. The results are expressed as the mean score for each domain and the mean overall score.
* The minimally important difference was found to be an improvement (or deterioration) of 0.5
- Secondary Outcome Measures
Name Time Method To compare changes in LCADL from baseline and after 6 weeks in the interventional arm compared with the control group 6 weeks Patients will undergo the assesment of the London Chest Activities of Daily Living at the time of study erollment and after 6 weeks of treatment with bioarginine or placebo.
The LCADL scale is a 15-item tool that measures the effect of dyspnea on routine daily activities. The LCADL provides a total score from 0 to 75 points with higher scores indicating greater limitations. Domain scores include personal care (0-20), domestic activities (0-30), physical activity (0-10), and leisure (0-15). The minimal detectable change (MDC) for the total score is 3.88 or approximately 4 points, 0.89 for personal care, 2.60 for domestic activities, 0.44 for physical activities, and 0.58 for leisure.
The minimal detectable change (MDC) for the total score is 3.88 or approximately 4 points, 0.89 for personal care, 2.60 for domestic activities, 0.44 for physical activities, and 0.58 for leisure.To compare changes in the distance covered during the 6MWT from baseline and after 6 weeks in the interventional arm compared with the control group 6 weeks Patiens will undergo the Six Minutes Walking Test at study enrolment and after 6 weeks of treatment with bioarginine or placebo.
The 6MWT will be conducted in room air conditions, in a corridor of 30 meters of lenght while the patients has being monitored with a pulsoxymeter that will register the peripheral oxygen saturation and heart right during the test. At the beginning and at the end of the test, Borg Dyspnea Scale (0-10 points), blood pressure and vitals will be registered. The patient will be asked to walk with a sutained pace for six minutes and the distance covered will be recorded. The mMCID of the 6MWT has been definied of 40 meter.To compare changes in the dyspnea domain of the CRQ from baseline and after 6 weeks in the interventional arm compared with the control group 6 weeks
Trial Locations
- Locations (1)
L. Sacco Hospital
🇮🇹Milan, Italy